Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Randomised, quadruple-blind, parallel-group study evaluating IV ketamine 0.5 mg/kg given once weekly for three weeks versus midazolam active placebo, each administered 24–72 hours before Prolonged Exposure (PE) therapy sessions.

Participants are Veterans with PTSD who receive adjunctive infusions plus a course of PE (three infusion-timed PE sessions followed by seven additional PE sessions); outcomes focus on PTSD symptom change and safety/tolerability.